Nintedanib Stada Nordic

Nintedanib, the active ingredient in Nintedanib Stada Nordic, is a tyrosine kinase inhibitor presented as a capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease and non‑small cell lung cancer in adult patients. The medication is manufactured under EU standards and is available by prescription.

GNH USA supplies Nintedanib Stada Nordic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is used to treat fibrotic lung disorders and certain cancers by targeting multiple growth factor receptors. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may occur with or without vomiting. - Abdominal pain: discomfort or cramps in the stomach area. - Elevated liver enzymes: increase in ALT/AST observed in laboratory tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Bleeding events: gastrointestinal or other bleeding, especially with anticoagulants. - Cardiovascular events: arterial thromboembolism or myocardial infarction.

When prescribing Nintedanib, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess ALT, AST and bilirubin before and during therapy. - Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors unless dose adjustment is made. - Bleeding risk: evaluate history of bleeding disorders and use of anticoagulants. - Pregnancy and lactation: contraindicated or not recommended due to unknown safety; avoid in pregnant or breastfeeding women. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nintedanib can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding. - P-glycoprotein inhibitors (e.g., verapamil): can raise plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - Diuretics: watch for dehydration that can worsen gastrointestinal side effects.